Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 3, 2010, Pages 223-235

  Hicar, Mark D ^a   Chen, Xuemin ^b,c   Briney, Bryan ^d   Hammonds, Jason ^b,c   Wang, Jaang Jiun ^b,c   Kalams, Spyros ^a,d   Spearman, Paul W ^b,c   Crowe Jr , James E ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibodies; HIV; humoral; immunity; monoclonal

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS ENVELOPE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD19; B-LYMPHOCYTES; CELLS, CULTURED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HIV; HUMANS; HYBRIDOMAS; IMMUNOGLOBULINS; MOLECULAR SEQUENCE DATA; PROTEIN MULTIMERIZATION; VIRION;

EID: 77954085035     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181dc98a3     Document Type: Article

References (50)

1. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science. 2008;321:530-532.
2. Johnston MI, Fauci AS. An HIV vaccine\challenges and prospects. N Engl J Med. 2008;359:888-890.
3. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;6:200-206.
4. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIVantibody2G12iseffectiveinprotectionagainst mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.
5. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Membrane Proximal External Region (MPER), protect against SHIVBa-L mucosal challenge. J Virol. 2010;84:1302-1313.
6. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207-210.
7. Srivastava IK, Ulmer JB, Barnett SW. Role of neutralizing antibodies in protective immunity against HIV. Hum Vaccin. 2005;1:45-60.
8. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med. 2007;262:5-25.
9. Humbert M, Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev. 2006;8:51-59.
10. Cleghorn F, Pape JW, Schechter M, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 2007;46:222-230.
11. Crooks ET, Moore PL, Franti M, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology. 2007;366:245-262.
12. Lin G, Nara PL. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res. 2007;5: 514-541.
13. Moore PL, Crooks ET, Porter L, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006;80:2515-2528.
14. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA. 2005;102:18514-18519. (Pubitemid 43011257)
15. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 2003;100:4144-4149.
16. Sagar M, Wu X, Lee S, et al. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol. 2006;80:9586-9598.
17. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6:231-243.
18. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA. 2005;102:14943-14948.
19. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 2006;24:739-769.
20. Zwick MB, Jensen R, Church S, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 2005;79:1252-1261.
21. Sun ZY, Oh KJ, Kim M, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity. 2008;28:52-63.
22. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285-289.
23. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol. 2001;75:1165-1171.
24. Earl PL, Broder CC, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol. 1994;68:3015-3026.
25. Hammonds J, Chen X, Fouts T, et al. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol. 2005;79:14804-14814.
26. Hammonds J, Chen X, Zhang X, et al. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine. 2007;25:8036-8048.
27. Weitkamp JH, Kallewaard N, Kusuhara K, et al. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J Immunol Methods. 2003;275:223-237.
28. Garrone P, Neidhardt EM, Garcia E, et al. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995;182: 1265-1273.
29. Ruiz M, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 2000;28:219-221.
30. Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev. 2006;58: 671-685.
31. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008;82:11651-11668.
32. Montefiori D. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. In: Coligan JE, Kruisbeek AM, Margulies DH, et al, eds. Current Protocols in Immunology. New York: John Wiley and Sons, Inc; 2004:1111-1117.
33. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79: 10108-10125.
34. Hammonds J, Chen X, Ding L, et al. Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. Virology. 2003;314:636-649.
35. Campbell EM, Perez O, Melar M, et al. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology. 2007;360:286-293.
36. Fouts T, Godfrey K, Bobb K, et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA. 2002;99: 11842-11847.
37. Varadarajan R, Sharma D, Chakraborty K, et al. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J Virol. 2005;79:1713-1723.
38. Visciano ML, Tuen M, Gorny MK, et al. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology. 2008;372:409-420.
39. Fondere JM, Huguet MF, Macura-Biegun A, et al. Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:114-119.
40. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458:636-640.
41. Choe H, Li W, Wright PL, et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell. 2003;114:161-170.
42. Huang CC, Venturi M, Majeed S, et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA. 2004;101:2706-2711.
43. Fouts TR, Binley JM, Trkola A, et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol. 1997;71:2779-2785.
44. Crooks ET, Moore PL, Richman D, et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies. 2005;14:101-113.
45. Tian C, Luskin GK, Dischert KM, et al. Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol. 2007;44:2173-2183.
46. Tian C, Luskin GK, Dischert KM, et al. Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. J Immunol. 2008; 180:3279-3288.
47. Weitkamp JH, Kallewaard N, Kusuhara K, et al. Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires. J Immunol. 2003;171:4680-4688.
48. Weitkamp JH, Kallewaard NL, Bowen AL, et al. VH1-46 is the dominant immunoglobulin heavy chain gene segment in rotavirus-specific memory B cells expressing the intestinal homing receptor alpha4beta7. J Immunol. 2005;174:3454-3460.
49. Weitkamp JH, Lafleur BJ, Greenberg HB, et al. Natural evolution of a human virus-specific antibody gene repertoire by somatic hypermutation requires both hotspot-directed and randomly-directed processes. Hum Immunol. 2005;66:666-676.
50. Weitkamp JH, Lafleur BJ, Crowe JE Jr. Rotavirus-specific CD5+ B cells in young children exhibit a distinct antibody repertoire compared with CD5-B cells. Hum Immunol. 2006;67:33-42.